{
  "docId": "019dd923-5f69-752d-a9b6-8fcc9601f794",
  "docSlug": "Kp30uSu3n5ioHQcbG5Ln",
  "documentTitle": "See the 20-slide pitch deck a psychedelics startup used to raise funds to build out a network of ketamine clinics",
  "authorId": "Pitchdecks",
  "authorName": "Novamind",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.777,
  "pageNumber": 9,
  "pageCount": 20,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a table to map drugs to indications and clinical outcomes, and two large circles to highlight market size metrics.",
  "elementsJson": [
    "action_title",
    "data_table",
    "big_number",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b6-8fcc9601f794/9",
  "deckHref": "/decks/019dd923-5f69-752d-a9b6-8fcc9601f794",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b6-8fcc9601f794.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b6-8fcc9601f794#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.255,
        "w": 0.255,
        "x": 0.683,
        "y": 0.229
      },
      "kind": "metric",
      "text": "US$224B US annual spend on mental health services",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d4bfe3e-7093-49db-a720-46b56d484233",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.17,
        "w": 0.17,
        "x": 0.815,
        "y": 0.518
      },
      "kind": "metric",
      "text": "US$17B US annual spend on depression and anxiety treatments",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d89a94be-b14f-43ae-9ecd-35ab7f566c5c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "US annual spend on mental health services: US$224B",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-9d6b-75cc-afe7-a2678df7aa33",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.14,
        "y": 0.83
      },
      "kind": "source-note",
      "text": "1-6: URLs for data sources",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62dcf44f-33cb-49ca-ac06-91881cb97c8b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.6,
        "x": 0.07,
        "y": 0.38
      },
      "kind": "table",
      "text": "Drug, Indication, Evidence. Ketamine, Prescribed off-label, A single infusion of ketamine can mitigate symptoms of suicidal ideation within 1 hour. Spravato, FDA approved for TRD & MDD, A single dose of esketamine can improve symptoms of depression and suicidal ideation within 2-4 hours. MDMA, Phase III for PTSD, Up to 12 months post-treatment, 67% of patients did not qualify for a PTSD diagnosis. Psilocybin, Phase IIB for TRD, 42% of patients treated with psilocybin were in complete remission 3 months post-treatment.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9400bc44-7254-4465-825c-b70a75ecff35",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.07,
        "y": 0.21
      },
      "kind": "title",
      "text": "Compelling clinical data is re-establishing the use of psychedelic medicines",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff90cc30-262d-47b4-83a2-db5d6061f971",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 8,
      "beatId": "34075010-0935-4808-8039-1ec116e0aa67",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Why",
      "beatSlug": "golden-circle-why",
      "evidence": "The 'why now' section explains the mental healthcare revolution",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Setup",
      "parentBeatSlug": "setup"
    },
    {
      "to": 10,
      "from": 9,
      "beatId": "950eabdb-9ce2-460a-a2e5-75883d7e52d1",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The market sizing section provides data on the clinical potential of psychedelic medicines",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 8,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "d985818c-8325-4605-826c-c2a192cec2d2",
      "evidence": "The 'why now' section sets up the urgency for the solution",
      "position": 0,
      "objective": "Why now is the right time for psychedelic medicines",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.7,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}